<DOC>
	<DOCNO>NCT01414257</DOCNO>
	<brief_summary>This Investigation perform purpose assess follow information long-term post-marketing daily medical practice patient receive REUMATOLEX 2 mg Capsule treatment Rheumatoid Arthritis ( RA ) dose high 8 mg/week . 1 . Condition occurrence ADRs 2 . Factors consider affect safety 3 . Verification efficacy</brief_summary>
	<brief_title>Methotrexate ( Rheumatrex ) High Dose Special Investigation ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>Implemented Special Investigation Central Registration System</detailed_description>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients need administer Rheumatrex order enrol survey Patients receive Rheumatrex dose high 8 mg/week treatment Rheumatoid Arthritis Patients treat Rheumatrex dose high 8 mg/week since day high dose therapy RA approve Patients treat MTX Rheumatrex administer Rheumatrex</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Rheumatrex</keyword>
	<keyword>High Dose</keyword>
</DOC>